All In Biotech

Drug Trial Radar · NCT05446298

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

58

Actual

Start

Dec 22, 2022

Primary completion

Aug 30, 2026

Study completion Aug 30, 2027

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; GOG Foundation
First posted
Jul 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

Conditions

  • Ovarian Cancer
  • High Grade Serous Adenocarcinoma of Ovary
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer

Interventions

  • ONC-392Drug

    ONC-392 will be given by IV infusion, q3w.

  • PembrolizumabDrug

    Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: 24 months
  2. Treatment Related Adverse Events (TRAEs) and Immune Related Adverse Events (irAEs)Time frame: 24 months

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Treatment Centers of America, Phoenix. 403

    Goodyear, Arizona

  • Honor Health, USOR, 406

    Phoenix, Arizona

  • Nuvance Health System, 401

    Danbury, Connecticut

  • Baptist MD Anderson Cancer Center, 404

    Jacksonville, Florida

  • Sudarshan Sharma, MD. LTD. 414

    Hinsdale, Illinois

  • Cancer Treatment Centers of America, Chicago. 410

    Zion, Illinois

  • Northwest Cancer Centers - Dyer, IN - USOR, 422

    Dyer, Indiana

  • Baptist Health Lexington, 407

    Lexington, Kentucky

  • Norton Cancer Institute - St. Matthews, 416

    Louisville, Kentucky

  • Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409

    Shreveport, Louisiana

  • Minnesota Oncology Hematology, P. A. - USOR, 421

    Maplewood, Minnesota

  • Center of Hope, 413

    Reno, Nevada

  • The Valley Hosptial, Inc. 411

    Ridgewood, New Jersey

  • Women's Cancer Care Associates, LLC. 405

    Albany, New York

  • The Ohio State University James Cancer Center, 412

    Columbus, Ohio

  • Oncology Associates of Oregon, P. C. - USOR. 419

    Eugene, Oregon

  • Texas Oncology, P. A. - Austin, USOR. 417

    Austin, Texas

  • Texas Oncology, P.A., Fort Worth - USOR. 420

    Fort Worth, Texas

  • Texas Oncology, P. A. Woodlands - USOR, 418

    The Woodlands, Texas

  • Texas Oncology - Northeast Texas - USOR, 423

    Tyler, Texas

  • Medical College of Wisconsin, 408

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.